Actinium Pharmaceuticals
ATNMActinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted radiotherapies for patients with solid tumors and hematologic malignancies.
Earnings
Next report
Nov 13, 2026 (in 2 months)Competitors
By market cap
Profile
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted radiotherapies for patients with solid tumors and hematologic malignancies. The company utilizes a biology-driven approach to create first-in-class radioconjugates that combine tumor-targeting antibodies with potent radioisotopes like Actinium-225 and Iodine-131. Their core value proposition lies in maximizing therapeutic efficacy while minimizing toxicity through precise delivery of radiation to cancer cells.
Actinium is a leader in the alpha-emitter space with a differentiated pipeline targeting novel antigens like CD33 and CD45, supported by internal cyclotron-based isotope production technology.
FAQ
- What is Actinium Pharmaceuticals's market cap?
- Actinium Pharmaceuticals (ATNM) has a market capitalization of $39.0M and trades on AMEX.
- Who are Actinium Pharmaceuticals's competitors?
- Actinium Pharmaceuticals's key competitors include Perspective Therapeutics, Eli Lilly, Bristol Myers Squibb, and others. These companies compete in similar markets and product categories.
- Who does Actinium Pharmaceuticals partner with?
- Actinium Pharmaceuticals's notable partners include National Cancer Institute, Novartis, AstraZeneca, and others.
- Where is Actinium Pharmaceuticals headquartered?
- Actinium Pharmaceuticals is headquartered in United States of America and employs approximately 49 people. It has been publicly traded since 2007.